Biologic agents in juvenile spondyloarthropathies - Wikidata - awgldk - TriplyDB

Biologic agents in juvenile spondyloarthropathies

Biologic agents in juvenile spondyloarthropathies

http://www.wikidata.org/entity/Q26766263

about

Juvenile Idiopathic Arthritis Multicenter inception cohort of enthesitis-related arthritis: variation in disease characteristics and treatment approaches

P2860

Q33572045-966F5DB4-BC63-401D-A720-F3FAE2F739AF Q33629843-1DCD10E9-6789-4915-8DEE-991E6E787107

P2860

Biologic agents in juvenile spondyloarthropathies

http://www.wikidata.org/entity/Q26766263

description

2016 nî lūn-bûn

@nan

2016 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի մարտին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

name

Biologic agents in juvenile spondyloarthropathies

@ast

Biologic agents in juvenile spondyloarthropathies

@en

Biologic agents in juvenile spondyloarthropathies

@nl

type

label

Biologic agents in juvenile spondyloarthropathies

@ast

Biologic agents in juvenile spondyloarthropathies

@en

Biologic agents in juvenile spondyloarthropathies

@nl

prefLabel

Biologic agents in juvenile spondyloarthropathies

@ast

Biologic agents in juvenile spondyloarthropathies

@en

Biologic agents in juvenile spondyloarthropathies

@nl

P1433

Q26766263-0A59617C-EC54-4C0A-9939-640F945A5D02

P1476

Q26766263-6D578A19-76FB-4BD2-A94C-7F75AB8A2E35

P2093

Q26766263-2F9BBCE2-BAA4-45A7-8A7E-89B0B0310B28

P275

Q26766263-48A8DFCC-08C3-40C5-B14C-D26C471ED51E

P2860

Q26766263-025A2861-1706-45D0-B150-905C1444DDA2

Q26766263-050EEACD-A401-4903-A7D5-7D7258C7CB1D

Q26766263-05B0EED1-FC85-4549-81D9-75838A0FC309

Q26766263-0BC2EECD-445C-4FB9-A693-CB999A3C8047

Q26766263-0BEBD2D8-47FD-42DD-A53F-87FE313B71A1

Q26766263-0EAD1F15-2FEC-46A7-9625-4C04A01607F4

Q26766263-143DCF05-7E88-451C-911E-53E7128D08A7

Q26766263-1F13BAF4-97F7-40C8-ACF6-90A66010A235

Q26766263-20648661-894A-46CC-A45E-578303227B19

Q26766263-2296C33D-8CB8-47D7-97B1-F118B18696C6

P2888

Q26766263-5EFE25DA-1C5F-4231-9E44-3205DD1DEE4D

P304

Q26766263-F40C2451-6850-4503-8780-538F86448A86

P31

Q26766263-2191591F-5FD4-45A0-B62E-56B0A261F1A9

Q26766263-9B48A385-0BAD-4D5F-B4B7-4D8304A4935A

P356

Q26766263-7CA66AAA-CA7E-4BB2-94BD-BD6AE50FC583

P407

Q26766263-C55396F5-CDFB-46E0-8CB9-214BFFD0AB3F

P433

Q26766263-E0CB01FD-7309-4680-8D04-ECE10830F9AF

P478

Q26766263-2BB6E191-C47C-4029-B07C-D1F8C2D96538

P50

Q26766263-04EE7018-496C-41CB-B8AC-A3A08FC914AD

P5008

Q26766263-DD490311-F7B5-4FB4-8D32-6AA7C84EF972

P577

Q26766263-52EE5C43-0690-47B2-A9F6-F33A97597A18

P5875

Q26766263-DF91ECCA-ACBF-46D3-9D71-ABCC7D4BB701

P6179

Q26766263-44A95222-D3ED-4F48-B858-F95D92EE5359

P698

Q26766263-483D1EE9-0848-40C8-8D15-870065DBE9FC

P921

Q26766263-E19FCE80-9FC0-44E7-BED4-6FFEE9E4323A

P932

Q26766263-6EA836FC-615C-4D50-9657-58FD96B5EFBE

P356

S12969-016-0076-6

P1433

Pediatric Rheumatology Online Journal

P1476

Biologic agents in juvenile spondyloarthropathies

@en

P2093

María Martha Katsicas

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

A proposed classification of the immunological diseases

Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*)

From HLA-B27 to spondyloarthritis: a journey through the ER.

Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study.

HLA-B27 associated spondyloarthropathy, an autoimmune disease based on crossreactivity between bacteria and HLA-B27?

High in vivo expression of interleukin-17 receptor in synovial endothelial cells and chondrocytes from arthritis patients.

Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010.

The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy.

Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy.

Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis.

P2888

s12969-016-0076-6

P304

17

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12969-016-0076-6

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

P5008

P577

2016-03-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

297892846

http://www.w3.org/2001/XMLSchema#string

P6179

1020181762

http://www.w3.org/2001/XMLSchema#string

P698

26968522

http://www.w3.org/2001/XMLSchema#string

P921

spondyloarthropathy

P932

4788890

http://www.w3.org/2001/XMLSchema#string